Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Global Breast Cancer Liquid Biopsy Market
The global breast cancer liquid biopsy market is projected to expand from USD 10.0 billion in 2025 to USD 18.77 billion by 2035, reflecting a CAGR of 6.5%. This growth is driven by increasing adoption of minimally invasive diagnostics, advancements in next-generation sequencing (NGS) and PCR platforms, and rising demand for early cancer detection and treatment monitoring. The market encompasses consumables and kits as primary segments, with applications spanning breast cancer and other malignancies.
North America leads the market, while Asia-Pacific exhibits the fastest growth trajectory.
Market size
Growth trajectory through 2035
Global Breast Cancer Liquid Biopsy Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 Technological Innovations
- Advances in NGS and PCR platforms have improved the sensitivity and specificity of liquid biopsy assays, enabling earlier and more accurate cancer detection.
-
Development 02 Clinical Validations
- Ongoing clinical studies and regulatory approvals for liquid biopsy platforms are expanding their clinical utility and adoption in breast cancer management.
-
Development 03 Partnerships and Collaborations
- Strategic alliances between diagnostic developers, pharmaceutical companies, and research institutions are accelerating innovation and commercialization of liquid biopsy technologies.
-
Development 04 Regulatory Updates
- Favorable regulatory policies and reimbursement frameworks for liquid biopsy assays are enhancing market penetration and adoption.
Emerging opportunities added
- Expansion in Emerging Markets Rapid growth in healthcare infrastructure and rising cancer awareness in Asia-Pacific and Latin America present significant opportunities for market expansion.
- Integration with Precision Oncology Liquid biopsy technologies align with the growing emphasis on precision oncology, enabling personalized treatment strategies and real-time monitoring of therapeutic efficacy.
- Partnerships and Collaborations Strategic alliances between diagnostic developers, pharmaceutical companies, and research institutions can accelerate innovation and commercialization of liquid biopsy platforms.
- Regulatory Support Favorable regulatory policies and reimbursement frameworks for liquid biopsy assays can enhance market penetration and adoption.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $10.00 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
top segment · 59.5% share
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- Regulatory Hurdles
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Technological Innovations: Advances in NGS and PCR platforms have improved the sensitivity and specificity of liquid biopsy assays, enabling earlier and more accurate cancer detection
+3 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 142-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Global Breast Cancer Liquid Biopsy Market today ($10.00 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- Which of Consumables, kits are the primary product segments, with kits gaining traction due to their ease of use and other tracked segments holds the largest share, and how do the growth rates diverge?
- How do North America, Europe, Asia-Pacific, Middle East & Africa compare on market share, growth rate, and regulatory posture?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Technological Advancements) and top restraints (led by Regulatory Hurdles), with quantified CAGR impact?
- What regulatory shifts and 4 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Technological Advancements Innovations in next-generation sequencing (NGS) and PCR platforms enhance sensitivity and specificity of liquid biopsy assays, enabling earlier and more accurate cancer detection.
- Rising Demand for Non-Invasive Diagnostics Liquid biopsies offer a minimally invasive alternative to traditional tissue biopsies, reducing patient discomfort and procedural risks while providing real-time tumor insights.
- Increasing Cancer Incidence The global rise in cancer cases, particularly breast cancer, drives demand for advanced diagnostic tools that support early detection, treatment selection, and monitoring.
- Regulatory and Clinical Validation Growing evidence from clinical studies and regulatory approvals for liquid biopsy platforms bolster market confidence and adoption among healthcare providers.
Restraints
Holding it back
- Regulatory Hurdles Stringent regulatory frameworks and prolonged approval timelines for new liquid biopsy assays may delay market entry and adoption.
- Limited Standardization Lack of standardized protocols for sample processing, assay validation, and result interpretation poses challenges for widespread clinical integration.
- Cost Constraints High costs associated with advanced liquid biopsy technologies and consumables may limit accessibility, particularly in lower-income regions.
- Clinical Skepticism Persistent skepticism among clinicians regarding the clinical utility and reliability of liquid biopsy results compared to traditional tissue biopsies may hinder adoption.
Trends
What we're watching
- The competitive landscape is shaped by the increasing integration of liquid biopsy technologies with precision oncology, the rise of NGS-based platforms, and the growing emphasis on minimally invasive diagnostics.
- Recent DevelopmentsTechnological Innovations Advances in NGS and PCR platforms have improved the sensitivity and specificity of liquid biopsy assays, enabling earlier and more accurate cancer detection.Clinical Validations: Ongoing clinical studies and regulatory approvals for liquid biopsy platforms are expanding th…
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Technological Advancements | +2.9% | Global | 2025–2035 |
| Rising Demand for Non-Invasive Diagnostics | +1.8% | Global | 2025–2035 |
| Increasing Cancer Incidence | +1.4% | Global | 2025–2035 |
| Regulatory and Clinical Validation | +1.0% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory Hurdles | −1.2% | Global | 2025–2029 |
| Limited Standardization | −0.8% | Global | 2025–2029 |
| Cost Constraints | −0.6% | Global | 2025–2029 |
The breast cancer liquid biopsy market is segmented by product, circulating biomarkers, platform comparison, and end-use industry.
Revenue share by type · 2025 base year
% OF $10.00 BN GLOBAL BREAST CANCER LIQUID BIOPSY MARKET · 2 TYPES COVERED
Each slice = that type's share of the total $10.00 Bn Global Breast Cancer Liquid Biopsy Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Consumables
-
kits are the primary product segments
-
with kits gaining traction due to their ease of use
-
standardized protocols
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $10.00 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~41.8% in 2025. The region dominates the market, driven by advanced healthcare infrastructure, high cancer incidence, and strong regulatory support for liquid biopsy technologies
Per-region detail
-
North America
The region dominates the market, driven by advanced healthcare infrastructure, high cancer incidence, and strong regulatory support for liquid biopsy technologies
-
Europe
Europe follows closely, with countries like Germany, France, and the UK leading in adoption due to robust healthcare systems and genomic medicine initiatives
-
Asia-Pacific
This region exhibits the fastest growth, fueled by increasing healthcare investments, rising cancer awareness, and expanding laboratory networks.Latin America and
-
Middle East & Africa
These regions present emerging opportunities, with growing demand for advanced diagnostics and improving healthcare access
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The breast cancer liquid biopsy market is moderately fragmented, with key players focusing on innovation, strategic partnerships, and geographic expansion to strengthen their market position.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of the global breast cancer liquid biopsy market?
The global breast cancer liquid biopsy market is expected to grow at 24% CAGR from 2022 to 2029. It is expected to reach above USD 1548.29 million by 2029 from USD 343.48 million in 2022. -
• What are some of the market's driving forces?
One of the most significant advantages of liquid biopsy is the reduced time required for the process. Tissue biopsy is obtained from limited sources, limiting the diagnostic information that clinicians may use to determine and evaluate the patient's response to therapy. Whereas tissue biopsies help doctors determine and make faster therapy decisions, liquid biopsies provide an easier way to understand the recurrence of cancer. -
• Which are the top companies to hold the market share in the breast cancer liquid biopsy market?
The veterinary reference laboratory market’s key players include F. Hoffmann Laboratories, The Menarini Group, NeoGenomics Laboratories, and Myriad Genetics. Inc, QLAGEN, Biocept. Inc, Sysmex. Inc, Fluxion Biosciences. Inc, Epic Science Inc, Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories, Myraid Genetics, Menarini Silicon Biosystems, Illumina, Cynvenio Biosystems Inc, and Genomic Health Inc, among others. -
• What is the leading application of the breast cancer liquid biopsy market?
Traditional breast cancer screening approaches, such as tissue biopsies, are unable to forecast or capture the complete genetic landscape of breast cancers. As an alternate approach for detecting breast cancer, liquid biopsy has a wide range of therapeutic uses, including screening, therapy selection, mutation detection, disease prognosis, and medication response and resistance in patients who are unable to undergo an invasive tumor biopsy. -
• Which is the largest regional market for breast cancer liquid biopsy market?
The Market’s largest share is in the North American region.
The Global Breast Cancer Liquid Biopsy Market is projected to reach $18.77 Bn by 2035, up from $10.00 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.